$アリゴス セラピューティクス インク(ALGS.US)$ NEWS Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study The data shows that the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ritonavir boosting. The PK profile supports twice daily ritonavir-free dosing without a food effect. Aligos has developed a robust clinical pipeline of three potentially best-in-class drug candidates. The presentation highlights the best-in-class potent...
1
1
報告
Jaguar8スレ主 :
At least an option while we prescribe Paxlovid
Aligos Therapeutics' P/S ratio remains below industry median due to poor revenue outlook. Without significant change, a drastic stock price rise is unlikely. The low P/S ratio is justified by inferior revenue forecasts.
The company anticipates the new appointments to be beneficial as they advance towards significant clinical data and strategically expand their team for Aligos' next growth phase. Both Tarazi and Aneja are thrilled to contribute to Aligos' mission in treating liver and viral diseases.
アリゴス セラピューティクス インクに関するコメント
NEWS
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
The data shows that the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ritonavir boosting.
The PK profile supports twice daily ritonavir-free dosing without a food effect.
Aligos has developed a robust clinical pipeline of three potentially best-in-class drug candidates.
The presentation highlights the best-in-class potent...
まだコメントはありません